Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

ISARIC (International Severe Acute Respiratory and emerging Infections Consortium) partnerships and outbreak preparedness initiatives enabled the rapid launch of standardised clinical data collection on COVID-19 in Jan 2020. Extensive global uptake of this resource has resulted in a large, standardised collection of comprehensive clinical data from hundreds of sites across dozens of countries. Data are analysed regularly and reported publicly to inform patient care and public health response. This report is a part of a series and includes the results of data analysis on 8 June 2020. We thank all of the data contributors for their ongoing support. As of 8JUN20, data have been entered for 67,130 patients from 488 sites across 37 countries. For this report, we show data for 42,656 patients with confirmed disease who were enrolled >14 days prior. This update includes about 2,400 new cases from France, and we thank these collaborators for this significant addition to the dataset. Some highlights from this report The median time from onset of symptoms to hospital admission is 5 days, but a proportion of patients take longer to get to the hospital (average 14.6 days, standard deviation 8.1). COVID-19 patients tend to require prolonged hospitalisation; of the 88% with a known outcome, the median length of admission to death or discharge is 8 days and the mean 11.5. 17% of patients were admitted to ICU/HDU, about 40% of these on the very day of hospital admission. Antibiotics were given to 83% of patients, antivirals to 9%, steroids to 15%, which becomes 93%, 50% and 27%, respectively for those admitted to ICU/HDU. Attention has been called on overuse of antibiotics and need to adhere to antibiotic stewardship principles. 67% of patients received some degree of oxygen supplementation: of these 23.4% received NIV and 15% IMV. This relatively high proportion of oxygen use will have implications for oxygen surge planning in healthcare facilities. Some centres may need to plan to boost capacity to deliver oxygen therapy if this is not readily available. WHO provides operational advice on surge strategy here https://apps.who.int/iris/bitstream/handle/10665/331746/WHO-2019-nCoV-Oxygen_sources-2020.1-eng.pdf

Original publication

DOI

10.1101/2020.07.17.20155218

Type

Journal article

Publication Date

25/07/2020